TY - JOUR
T1 - Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis
AU - Verbsky, James W.
AU - White, Andrew J.
PY - 2004/10
Y1 - 2004/10
N2 - Systemic onset juvenile rheumatoid arthritis (SOJRA) is a multisystem disease characterized by high fever, rash, arthritis, serositis, splenomegaly, and laboratory evidence of systemic inflammation. Anticytokine therapies show promise in the treatment of chronic arthritides in children. We describe the use of the recombinant interleukin 1 receptor antagonist anakinra in 2 patients with therapy resistant SOJRA. Both patients experienced immediate and sustained resolution of symptoms and laboratory markers of inflammation, in one case after years of treatment with other immunosuppressive therapies.
AB - Systemic onset juvenile rheumatoid arthritis (SOJRA) is a multisystem disease characterized by high fever, rash, arthritis, serositis, splenomegaly, and laboratory evidence of systemic inflammation. Anticytokine therapies show promise in the treatment of chronic arthritides in children. We describe the use of the recombinant interleukin 1 receptor antagonist anakinra in 2 patients with therapy resistant SOJRA. Both patients experienced immediate and sustained resolution of symptoms and laboratory markers of inflammation, in one case after years of treatment with other immunosuppressive therapies.
KW - Anakinra
KW - Hemophagocytic syndrome
KW - Infliximab
KW - Juvenile onset still disease
KW - Juvenile rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=5044223401&partnerID=8YFLogxK
M3 - Article
C2 - 15468378
AN - SCOPUS:5044223401
SN - 0315-162X
VL - 31
SP - 2071
EP - 2075
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 10
ER -